Epiomed Therapeutics Inc.
Drugs to tackle all forms of nausea and vomiting
This article was originally published in Start Up
The various triggers that case nausea and vomiting are conveyed to the brain via different pathways that converge to create a final common pathway leading to the vomiting center in the medulla region of the brain. Previous attempts to develop drugs that target this common pathway have failed in the clinic because they produced anxiety and panic attacks, but Epiomed Therapeutics Inc. thinks it has discovered the reasons for the anxiety and is developing a redesigned product devoid of this side effect.
You may also be interested in...
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways
Redx Pharma PLC and its subsidiaries are focused on developing proprietary, small-molecule therapeutics to address areas of high unmet medical need principally in cancer, infection and autoimmune disease.